Although IGF-1 has known neurotrophic properties, early and sustained exposure to the (1-3)IGF-1 analog did not ameliorate structural-, metabolic-, or seizure-related abnormalities and produced detrimental behavioral effects in this model of cortical malformation. These findings underscore the importance of developmental timing and molecular specificity when applying IGF-1-based interventions and caution against the assumption that earlier or prolonged treatment is necessarily beneficial in malformed cortical circuits.
Lee et al. (Wed,) studied this question.